Drugs / recombinant tissue plasminogen activator
recombinant tissue plasminogen activator
Trials 11
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00001713 | Feb 1998 → Jan 2006 | thrombophlebitis | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04356833 | Apr 2020 → Mar 2021 | COVID-19 | University College, London | Completed | No outcome recorded |
| Phase 2 | NCT01678495 | Aug 2012 → Jun 2015 | cerebral infarction | Sant Pau Research Institute | Completed | No outcome recorded |
| Phase 2 | NCT00243906 | Jan 2003 → May 2006 | stroke disorder | University of Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT00029315 | Sep 2001 → Sep 2004 | hemorrhagic stroke | Johns Hopkins University | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT02767232 | Jul 2018 → Apr 2023 | post-thrombotic syndrome, venous thromboembolism | University of Colorado, Denver | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT03966079 | Jan 2017 → Jan 2020 | pulmonary embolism | Beijing Tsinghua Chang Gung Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01513759 | Jun 2012 → Feb 2013 | pulmonary embolism | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT02396758 | Jun 2015 → Apr 2019 | pulmonary embolism | Boston Scientific Corporation | Completed | No outcome recorded |
| Phase 4 | NCT02355743 | Feb 2015 → Sep 2016 | short bowel syndrome | University of Pittsburgh | Completed | No outcome recorded |
| Phase 4 | NCT01531829 | Jul 2009 → Jul 2012 | pulmonary embolism | Beijing Chao Yang Hospital | Unknown | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 2 | NCT01869478 Comparator | Jan 2013 → Sep 2015 | ischemic stroke | Mayo Clinic | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT01133223 Comparator | May 2010 → Sep 2015 | stroke disorder | Hospital de Clinicas de Porto Alegre | Withdrawn | No outcome recorded |
| Phase 4 | NCT05155540 Comparator | Jul 2019 → Jul 2020 | cerebral atherosclerosis, ischemic stroke, venous thromboembolism | Alexandria University | Completed | No outcome recorded |
| — | NCT07374978 Comparator | Jul 2023 → May 2025 | pulmonary embolism | Ain Shams University | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant tissue plasminogen activator | “once weekly recombinant tissue plasminogen activator (rtPA) lock therapy more effective than routine care using heparin flushes” NCT02355743 ↗14“intravenous recombinant tissue plasminogen activator (rt-PA)” NCT01869478 ↗ |
| Known as | rt-PA | “The purpose of this study is to examine the effects of delivering intra-arterial recombinant tissue plasminogen activator (rt-PA) and ultrasound to the site of the blood clot...” NCT00243906 ↗2“Patients received a nebulised version of a type of drug called tissue plasminogen activator (rt-PA) that was inhaled using a nebuliser.” NCT04356833 ↗ “Recombinant Tissue Plasminogen Activator (rt-PA)” NCT00029315 ↗ |
| Known as | tissue plasminogen activator | “Patients received a nebulised version of a type of drug called tissue plasminogen activator (rt-PA) that was inhaled using a nebuliser.” NCT04356833 ↗ |
| Known as | tPA | “The aim of this study was to determine the lowest optimal tissue plasminogen activator (tPA) dose and delivery duration using” PMID 30025734 ↗ Jul 2018 |
| Modality | Protein / enzyme biologic | “Recombinant tissue plasminogen activator” NCT01133223 ↗ |
| Route | Intravenous | “combined intravenous (IV) and intra-arterial (IA) recombinant tissue plasminogen activator” NCT00243906 ↗ |
| Route | Other | “combined intravenous (IV) and intra-arterial (IA) recombinant tissue plasminogen activator” NCT00243906 ↗ |